Holen Sie sich die Stockscreener-App
299.17
2.47%
-7.59
Handel nachbörslich:
303.71
4.54
+1.52%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals: Strengthened Financial Position and Promising Pipeline Expansion Drive Buy Rating - TipRanks
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MyChesCo
Madrigal Pharmaceuticals secures $500M credit facility from Blue Owl - MSN
What drives Madrigal Pharmaceuticals Inc. stock priceHigh-velocity gains - Autocar Professional
Is Madrigal Pharmaceuticals Inc. a good long term investmentHigh-profit trading signals - jammulinksnews.com
What analysts say about Madrigal Pharmaceuticals Inc. stockSuperior portfolio returns - jammulinksnews.com
Madrigal Pharmaceuticals Secures $500 Million in Senior - GlobeNewswire
Madrigal's $500M Financing: Cementing Leadership in the High-Growth MASH Market - AInvest
Madrigal Pharmaceuticals Secures $500M Credit Facility - TipRanks
Madrigal Pharmaceuticals (MDGL) Secures $500 Million Credit Facility - GuruFocus
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured - GuruFocus
Madrigal secures $500 million credit facility to advance MASH pipeline By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals Secures $500 Million Senior Secured Credit Facility to Enhance MASH Pipeline and Support Strategic Expansion - Quiver Quantitative
Citizens JMP reiterates Madrigal stock rating on strong Rezdiffra uptake By Investing.com - Investing.com Canada
10 Most Undervalued Healthcare Stocks To Buy According To Analysts - Insider Monkey
Madrigal Pharmaceuticals Inc. Stock Analysis and ForecastConsistently outstanding ROI - Autocar Professional
Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy - MSN
Madrigal Pharmaceuticals Secures Key Patent for Rezdiffra, Extending Market Protection to 2044 - MSN
Madrigal gains after Rezdiffra patent win - MSN
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights - MSN
Madrigal Pharmaceuticals Grants Equity Awards to 30 New Team Members - MSN
Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? - Yahoo Finance
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com
Madrigal Pharmaceuticals receives notice of allowance for Rezdiffra patent - TipRanks
Madrigal Pharmaceuticals Surges to 222nd in Daily Rankings with $451 Million Turnover - AInvest
Madrigal Pharmaceuticals: Strong Surge or Overpriced? - StocksToTrade
Madrigal Pharmaceuticals stock price target raised by Oppenheimer on patent news - Investing.com Canada
Madrigal’s Surge: Breakthrough in Liver Treatment? - timothysykes.com
Madrigal Pharmaceuticals Soars: Is It Time to Buy? - StocksToTrade
Madrigal Pharmaceuticals (MDGL) Surges Over 12% in Market Gains - GuruFocus
Madrigal Pharmaceuticals (MDGL) Soars on Rezdiffra Patent Approval - GuruFocus
Madrigal gains after Rezdiffra patent win (MDGL:NASDAQ) - Seeking Alpha
Madrigal stock jumps as patent protection for MASH treatment extended By Investing.com - Investing.com Nigeria
Madrigal stock jumps as patent protection for MASH treatment extended - Investing.com
Madrigal receives patent allowance for MASH treatment Rezdiffra By Investing.com - Investing.com Nigeria
Why Madrigal Pharmaceuticals Inc. stock attracts strong analyst attentionFree Stock Investment Growth Plan - beatles.ru
Madrigal Pharmaceuticals (MDGL) Secures Patent for Rezdiffra Use - GuruFocus
Madrigal receives patent allowance for MASH treatment Rezdiffra - Investing.com
Madrigal Pharmaceuticals Announces FDA Patent Allowance for Rezdiffra™ Providing Protection Through September 2044 - Quiver Quantitative
Madrigal Pharmaceuticals Receives Notice of Allowance from - GlobeNewswire
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom) - Yahoo Finance
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit - 富途牛牛
3.30%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):